IMerge: Updated Safety and Efficacy Data on Imetelstat for Lower-Risk MDS


Hematology experts highlight recent data updates from the IMerge trial on the telomerase inhibitor imetelstat, which is being studied for lower-risk MDS.


Amer Zeidan, MBBS: We can talk more about the advances we’ve seen in lower-risk MDS [myelodysplastic syndromes]. There have been a couple of updates on 2 of the most promising drugs that we have in the lower-risk MDS space: imetelstat and luspatercept. Luspatercept is already approved. Imetelstat has completed its phase 3 trial, and we’re expecting results in 2023. Can you highlight your thoughts and some of the recent updates?

Rami Komrokji, MD: Let’s start with imetelstat. This is a telomerase inhibitor that finished phase 3 study. Hopefully, we’ll have the readout in January or February. We hope it will be positive because that will lead to a new drug approval for lower-risk MDS. The phase 2 study has been published in Journal of Clinical Oncology. Dr [Uwe] Platzbecker presented data on a subset of patients at ASH [American Society of Hematology Annual Meeting] that had durable response. Imetelstat is an IV [intravenous] infusion given every 4 weeks. In the phase 2 data, around 42% of the patients became transfusion independent, and a subset of patients had a durable transfusion independence for more than a year.

At ASH, there was a focus on that subset of patients. Eleven patients had more than 1 year of transfusion independency. Most of them [had] MDS with ring sideroblasts or the SF3B1-mutant type. Those patients had durable responses. Interestingly, in patients with SF3B1, we see a signal of reduction on the allele burden, suggesting that this can be disease modifying. In terms of safety, the drug does cause myelosuppression, so patients can develop grade 3 or 4 thrombocytopenia or neutropenia. Most of them are reversible by the second round of treatment. This was an update on the transfusion dependency, but the data look strong from the phase 2 trial, and we hope that the phase 3 trial will confirm the signal and lead to approval.

Transcript edited for clarity.

Related Videos
Lori A. Leslie, MD
Changchun Deng, MD, PhD
Guenther Koehne, MD, PhD
Ibrahim Aldoss, MD
Andrew P. Jallouk, BS, MD, PhD, assistant professor, Vanderbilt University
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Ibrahim Aldoss, MD
Kateryna Fedorov, MD, assistant professor, hematology-oncology, Vanderbilt University Medical Center
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Annie Im, MD, FASCO